116 related articles for article (PubMed ID: 8779803)
1. Augmentative effects of phytohemagglutinin-P on proliferation and cytotoxicity of interleukin-2-activated canine peripheral blood lymphocytes.
Mizuno S; Fujinaga T; Kurosawa T
Zentralbl Veterinarmed A; 1996 Jul; 43(5):289-96. PubMed ID: 8779803
[TBL] [Abstract][Full Text] [Related]
2. Changes in lymphokine-activated killer activity in peripheral blood lymphocytes from canine transmissible venereal sarcoma models.
Mizuno S; Fujinaga T; Kurosawa T
Exp Anim; 1996 Jul; 45(3):289-92. PubMed ID: 8840150
[TBL] [Abstract][Full Text] [Related]
3. Long-term cultures of human peripheral blood lymphocytes with recombinant human interleukin-2 generate a population of virtually pure CD3+ CD16- CD56- large granular lymphocyte LAK cells.
Roussel E; Gerrard JM; Greenberg AH
Clin Exp Immunol; 1990 Nov; 82(2):416-21. PubMed ID: 1700746
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxicity against autologous, allogeneic, and xenogeneic tumor targets by human recombinant interleukin-2-activated lymphocytes from healthy dogs and dogs with lung tumors.
Mitchell DH; Withrow SJ; Johnston MR; Kruse CA
Am J Vet Res; 1991 Jul; 52(7):1132-6. PubMed ID: 1892269
[TBL] [Abstract][Full Text] [Related]
5. Natural killer (NK) and lymphokine-activated killer (LAK) cell functions from healthy dogs and 29 dogs with a variety of spontaneous neoplasms.
Funk J; Schmitz G; Failing K; Burkhardt E
Cancer Immunol Immunother; 2005 Jan; 54(1):87-92. PubMed ID: 15693143
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-2-activated lymphocytes from brain tumor patients. A comparison of two preparations generated in vitro.
Kruse CA; Mitchell DH; Lillehei KO; Johnson SD; McCleary EL; Moore GE; Waldrop S; Mierau GW
Cancer; 1989 Oct; 64(8):1629-37. PubMed ID: 2790675
[TBL] [Abstract][Full Text] [Related]
7. Lymphokine-activated killer cells in rats. IV. Developmental relationships among large agranular lymphocytes, large granular lymphocytes, and lymphokine-activated killer cells.
Maghazachi AA; Vujanovic NL; Herberman RB; Hiserodt JC
J Immunol; 1988 Apr; 140(8):2846-52. PubMed ID: 3258622
[TBL] [Abstract][Full Text] [Related]
8. On the relative roles of interleukin-2 and interleukin-10 in the generation of lymphokine-activated killer cell activity.
Spagnoli GC; Juretic A; Schultz-Thater E; Dellabona P; Filgueira L; Hörig H; Zuber M; Garotta G; Heberer M
Cell Immunol; 1993 Feb; 146(2):391-405. PubMed ID: 8174177
[TBL] [Abstract][Full Text] [Related]
9. Induction of lymphokine-activated killer activity by interleukin 4 in human lymphocytes preactivated by interleukin 2 in vivo or in vitro.
Higuchi CM; Thompson JA; Lindgren CG; Gillis S; Widmer MB; Kern DE; Fefer A
Cancer Res; 1989 Dec; 49(23):6487-92. PubMed ID: 2479463
[TBL] [Abstract][Full Text] [Related]
10. Apoptotic killing of CD4+ T lymphocytes in HIV-1-infected PHA-stimulated PBL cultures is mediated by CD8+ LAK cells.
Wang L; Klimpel GR; Planas JM; Li H; Cloyd MW
Virology; 1998 Feb; 241(2):169-80. PubMed ID: 9499792
[TBL] [Abstract][Full Text] [Related]
11. Proliferation and cytotoxicity of lectin-induced lymphokine-activated killer (LILAK) cells.
Shimizu Y; Kuroki T; Shiomi S; Kobayashi K; Monna T
J Gastroenterol Hepatol; 1991; 6(5):485-90. PubMed ID: 1657242
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of basic procedures for adoptive immunotherapy for gastric cancer.
Fujimoto T; Omote K; Mai M; Natsuume-Sakai S
Biotherapy; 1992; 5(2):153-63. PubMed ID: 1524956
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of interleukin-6-enhanced lymphokine-activated killer cell function.
Iho S; Shau HY; Golub SH
Cell Immunol; 1991 Jun; 135(1):66-77. PubMed ID: 2018984
[TBL] [Abstract][Full Text] [Related]
14. Human recombinant IL-4 suppresses the induction of human IL-2 induced lymphokine activated killer (LAK) activity.
Brooks B; Rees RC
Clin Exp Immunol; 1988 Nov; 74(2):162-5. PubMed ID: 3265652
[TBL] [Abstract][Full Text] [Related]
15. Role of proliferation in LAK cell development.
Ramsdell FJ; Shau H; Golub SH
Cancer Immunol Immunother; 1988; 26(2):139-44. PubMed ID: 3129192
[TBL] [Abstract][Full Text] [Related]
16. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues.
Colquhoun SD; Economou JS; Shau H; Golub SH
J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167
[TBL] [Abstract][Full Text] [Related]
17. Generation of stimulated, lymphokine activated T killer (T-LAK) cells from the peripheral blood of normal donors and adult patients with recurrent glioblastoma.
Yamamoto RS; Coss J; Vayuvegula B; Gupta S; Beamer Y; Jacques S; Jeffes EW; Carson WE; Jakowatz J; Granger GA
J Immunol Methods; 1991 Mar; 137(2):225-35. PubMed ID: 2013699
[TBL] [Abstract][Full Text] [Related]
18. [Experimental studies on induction of various lymphokine-activated killer cells using recombinant interleukin 2].
Takao H; Saji S; Sugiyama Y; Tachibana S; Goshima H; Morita T; Sakata K
Nihon Geka Gakkai Zasshi; 1988 May; 89(5):646-54. PubMed ID: 3261830
[TBL] [Abstract][Full Text] [Related]
19. Successful in vivo generation of canine lymphokine-activated killer cells by continuous recombinant interleukin-2 infusion through the splenic artery.
Ohnishi H; Okuno K; Yasutomi M
Cancer Biother; 1993; 8(3):213-22. PubMed ID: 7804361
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-2 modulates the expression of lymphocyte function-associated antigen-one (LFA-1) and p150,95 during the generation of lymphokine-activated killer (LAK) cells.
Grant AJ; Merchant RE; Hall RE
Immunology; 1989 Jan; 66(1):117-24. PubMed ID: 15493273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
